Alitretinoin for severe chronic hand eczema: A NICE single technology appraisal

PharmacoEconomics

Volumn 28, Issue 5, 2010, Pages 351-362

  Rodgers, Mark ^a   Griffin, Susan ^b   Paulden, Mike ^b   Slack, Russell ^a   Duffy, Steven ^a   Ingram, John R ^c   Woolacott, Nerys ^a   Sculpher, Mark ^b  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; STEROID; TOCTINO; UNCLASSIFIED DRUG;

CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; HAND ECZEMA; HEALTH ECONOMICS; HUMAN; PATIENT ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN PROTECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

DERMATOLOGIC AGENTS; ECZEMA; HAND DERMATOSES; HUMANS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TRETINOIN;

EID: 77951479060     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11532160-000000000-00000     Document Type: Review

References (18)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE, 2006 [online]. Available from URL: http://www.nice. org.uk/page.aspx?o=STAprocessguide [Accessed 2009Mar 1]
2. National Institute for Health and Clinical Excellence. Eczema (chronic): alitretinoin [online]. Available from URL: http://www.nice.org.uk/guidance/ index.jsp?action= byID&o=12035 [Accessed 2009 Dec 2]
3. Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis 2007 Oct; 57 (4): 203-210 (Pubitemid 47397793)
4. Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis 2008; 59 (1): 43-47 (Pubitemid 351990048)
5. Cvetkovski RS, Rothman KJ, Olsen J, et al. Relation between diagnoses on severity, sick leave and loss of job among patients with occupational hand eczema. Br J Dermatol 2005; 152 (1): 93-98 (Pubitemid 40193839)
6. Meding B,Wrangsjo K, Jarvholm B. Fifteen-year follow-up of hand eczema: persistence and consequences. Br J Dermatol 2005; 152 (5): 975-980 (Pubitemid 40704938)
7. Halpern SM, Anstey AV, Dawe RS, et al. Guidelines for topical PUVA: a report of a workshop of the British photodermatology group. Br J Dermatol 2000 Jan; 142 (1): 22-31
8. Akhaven A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppresive agents. Clin Dermatol 2003; 21 (3): 225-240 (Pubitemid 36629334)
9. Basilea Pharmaceuticals Ltd. Toctino 10 mg and 30mg soft capsules. SPC. electronic Medicines Compendium (eMC), 2008 [online]. Available from URL: http://emc.medicines. org.uk/medicine/21177/SPC/Toctino10mgand30mg softcapsules/ [Accessed 2009 Dec 2]
10. National Institute for Health and Clinical Excellence. Eczema (chronic) alitretinoin: manufacturer submission [online]. Available from URL: http://www.nice.org.uk/guidance/ index.jsp?action=folder&o=43972 [Accessed 2009 Dec 2]
11. Ruzicka T, Lynde CW, Jemec GBE, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol 2008; 158 (4): 808-817
12. Ruzicka T, Lahfa M, Lynde CH, et al. Re-treatment study of alitretinoin (9-cis retinoic acid) in severe chronic hand eczema refractory to topical treatment [abstract no. P-280]. 16th Congress of the European Academy of Dermatology and Venereology (EADV); 2007 May 16-20; Vienna
13. Ruzicka T, Larsen FG, Galewicz D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004; 140 (12): 1453-1459 (Pubitemid 39627436)
14. Reference sheet: excerpts from clinical study report. Safety and efficacy of alitretinoin in severe refractory chronic hand dermatitis [protocol BAP00200/report BAP00983; reference number DOF-ALI08021]. Basel: Basilea Pharmaceuticals Ltd, 2008. (Data on file)
15. Reference sheet: Augustin quality of life in patients with hand eczema [unpublished abstract; academic in confidence; reference number DOF-ALI08018]. Basel: Basilea Pharmaceuticals Ltd, 2008. (Data on file)
16. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 [online]. Available from URL: http://www.nice.org. uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2009 Dec 2]
17. Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technology Assessment 2006; 10 (46): 1-233
18. National Institute for Health and Clinical Excellence. Final appraisal determination: alitretinoin for the treatment of severe chronic hand eczema. London: NICE, 2009 Jul [online]. Available from URL: http://www.nice.org.uk/ nicemedia/pdf/EczemaFAD.pdf [Accessed 2009 Dec 2]